Beijing Capital Agribusiness has acquired the license to Britain-based Genus' virus-resistant biotech pigs. Under the terms of the deal, Genus will get upfront and milestone payments of $20 million, and Beijing Shou Nong Future Bio-Tech, which will soon be launched by BCA, will fund the development of the pigs, which are resistant to porcine reproductive and respiratory syndrome, and seek its regulatory approval in China.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.